MeSH term
Frequency | Condition_Probility | Animals | 34 | 0.0 |
Humans | 148 | 0.0 |
Genes, Dominant | 2 | 0.0 |
*Microsatellite Repeats | 3 | 1.0 |
Phenotype | 11 | 0.0 |
Research Support, Non-U.S. Gov't | 100 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 36 | 0.0 |
*Trinucleotide Repeat Expansion | 8 | 18.0 |
Adult | 70 | 0.0 |
Base Sequence | 18 | 0.0 |
Case-Control Studies | 11 | 0.0 |
DNA/genetics | 3 | 0.0 |
Male | 93 | 0.0 |
Myotonic Dystrophy/classification/complications/*genetics | 2 | 100.0 |
Risk Factors | 8 | 0.0 |
Diabetes Mellitus, Type 1/*complications | 2 | 7.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Aged | 22 | 0.0 |
DNA/analysis/genetics | 2 | 1.0 |
Female | 85 | 0.0 |
Middle Aged | 40 | 0.0 |
Myotonic Dystrophy/*genetics/*physiopathology | 2 | 100.0 |
English Abstract | 13 | 0.0 |
Brain/metabolism | 2 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Mice | 21 | 0.0 |
Mice, Knockout | 6 | 0.0 |
Molecular Sequence Data | 16 | 0.0 |
Muscle, Skeletal/metabolism | 3 | 1.0 |
Myotonic Dystrophy/*genetics/pathology | 4 | 50.0 |
Polymerase Chain Reaction | 11 | 0.0 |
Transfection | 2 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Alleles | 11 | 0.0 |
Child | 27 | 0.0 |
Genetic Markers | 5 | 0.0 |
Genotype | 6 | 0.0 |
HLA-DR Antigens/*genetics | 3 | 0.0 |
Pedigree | 10 | 0.0 |
Blotting, Southern | 5 | 0.0 |
DNA Primers | 8 | 0.0 |
Mice, Transgenic | 9 | 0.0 |
Proteins/genetics | 2 | 0.0 |
Trinucleotide Repeat Expansion/*genetics | 10 | 16.0 |
Treatment Outcome | 2 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
*Drosophila Proteins | 3 | 0.0 |
Myotonic Dystrophy/*genetics | 16 | 24.0 |
Nuclear Proteins/*genetics/metabolism | 2 | 1.0 |
Phylogeny | 3 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Child, Preschool | 17 | 0.0 |
Infant | 13 | 0.0 |
Infant, Newborn | 5 | 0.0 |
Pregnancy | 6 | 0.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics | 10 | 3.0 |
Reference Values | 10 | 0.0 |
Trinucleotide Repeats/*genetics | 5 | 6.0 |
Adolescent | 34 | 0.0 |
In Vitro | 2 | 0.0 |
Regression Analysis | 4 | 0.0 |
Blotting, Western | 7 | 0.0 |
Cells, Cultured | 12 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Organ Specificity | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
Transgenes/genetics | 2 | 2.0 |
Age Factors | 8 | 0.0 |
Diabetes Mellitus, Type 1/*epidemiology | 4 | 66.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Homeodomain Proteins/genetics | 3 | 1.0 |
Protein-Serine-Threonine Kinases/genetics | 7 | 5.0 |
*Gene Expression Regulation | 3 | 0.0 |
Myotonic Dystrophy/etiology/*genetics | 2 | 100.0 |
Trinucleotide Repeat Expansion | 5 | 13.0 |
Family Health | 4 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Trinucleotide Repeat Expansion/genetics | 5 | 12.0 |
Trinucleotide Repeats/genetics | 7 | 11.0 |
Gene Frequency | 2 | 0.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
*Trinucleotide Repeats | 4 | 3.0 |
Age of Onset | 8 | 0.0 |
Disease Progression | 4 | 0.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Time Factors | 5 | 0.0 |
Comparative Study | 25 | 0.0 |
Prognosis | 3 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
Blood Glucose/analysis | 4 | 0.0 |
Diabetes Mellitus, Type 1/*metabolism | 3 | 5.0 |
Hemoglobin A, Glycosylated/analysis | 3 | 0.0 |
Sex Factors | 2 | 0.0 |
Autoantibodies/blood | 3 | 1.0 |
Antibody Specificity | 3 | 0.0 |
Cell Division | 2 | 0.0 |
In Situ Hybridization | 5 | 0.0 |
Muscle, Skeletal/*metabolism/pathology | 2 | 12.0 |
Fasting | 2 | 0.0 |
Insulin/therapeutic use | 2 | 1.0 |
Sex Distribution | 4 | 1.0 |
Cell Line | 6 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
*Founder Effect | 3 | 2.0 |
Haplotypes/*genetics | 2 | 1.0 |
Insulin Resistance/*genetics | 2 | 2.0 |
Myotonic Dystrophy/*genetics/physiopathology | 2 | 66.0 |
RNA/genetics | 2 | 1.0 |
Receptor, Insulin/*genetics | 2 | 5.0 |
Chromosome Mapping | 3 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
Mutation | 10 | 0.0 |
Myotonic Dystrophy/*genetics/metabolism | 2 | 50.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
3' Untranslated Regions/genetics | 3 | 3.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
RNA-Binding Proteins/genetics/*metabolism | 2 | 3.0 |
Body Composition | 3 | 1.0 |
Electric Impedance | 2 | 3.0 |
Insulin/blood | 3 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Glucose Clamp Technique/methods | 2 | 100.0 |
Brain/*pathology | 3 | 1.0 |
Clinical Trials, Phase I | 2 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
RNA-Binding Proteins/genetics | 4 | 7.0 |
Questionnaires | 5 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
*Alleles | 2 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
Mutation/genetics | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Chromosomes, Human, Pair 19 | 4 | 2.0 |
Diagnosis, Differential | 2 | 0.0 |
Cell Differentiation/*physiology | 2 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Calorimetry, Indirect | 3 | 5.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Hela Cells | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Prevalence | 8 | 0.0 |
Exons/genetics | 2 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Predictive Value of Tests | 5 | 0.0 |
*Seasons | 3 | 7.0 |
Mice, SCID | 2 | 0.0 |
Mosaicism | 2 | 2.0 |
*Diabetes Mellitus, Type 1 | 2 | 50.0 |
Neurologic Examination | 2 | 1.0 |
*Pregnancy Complications | 2 | 5.0 |
Prospective Studies | 3 | 0.0 |
Muscle, Skeletal/pathology | 2 | 3.0 |
Child Welfare | 2 | 8.0 |
Diabetes Mellitus, Type 1/*complications/epidemiology | 2 | 100.0 |
Statistics | 2 | 0.0 |
Retrospective Studies | 4 | 0.0 |
Severity of Illness Index | 7 | 0.0 |
Genomic Instability | 2 | 12.0 |
Blood Glucose/*metabolism | 3 | 1.0 |
Aged, 80 and over | 4 | 0.0 |
Alternative Splicing/*genetics | 2 | 1.0 |
Glucose/metabolism | 2 | 0.0 |
Genetic Markers/genetics | 2 | 0.0 |
Blotting, Northern/methods | 2 | 3.0 |
Myotonic Dystrophy/genetics/*metabolism | 2 | 66.0 |
RNA/*metabolism | 2 | 3.0 |
Muscle, Skeletal/physiopathology | 3 | 15.0 |
Neoplasm Transplantation | 2 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Myotonic Dystrophy/*genetics/*psychology | 2 | 66.0 |
Socioeconomic Factors | 2 | 1.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Myotonic Dystrophy/*complications/genetics | 2 | 66.0 |
Blotting, Northern | 4 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Binding Sites | 2 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Models, Biological | 2 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
*Chromosomes, Human, Pair 3 | 3 | 0.0 |
Hamsters | 2 | 0.0 |
*DNA-Binding Proteins | 3 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Body Mass Index | 3 | 0.0 |
Cross-Over Studies | 2 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Hemoglobin A, Glycosylated/metabolism | 2 | 1.0 |
Blood Glucose | 2 | 2.0 |
C-Peptide/blood | 2 | 1.0 |
Haplotypes | 2 | 0.0 |
Introns | 2 | 0.0 |
Myotonic Dystrophy/classification/*genetics | 2 | 100.0 |
Base Pairing | 2 | 3.0 |
Seasons | 2 | 1.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 2 | 3.0 |
HLA-DQ Antigens/*genetics | 2 | 0.0 |
Histocompatibility Testing | 2 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Thyroid Function Tests | 2 | 2.0 |
*Sex Characteristics | 2 | 1.0 |
Vibration | 2 | 14.0 |
Incidence | 3 | 0.0 |
Disability Evaluation | 2 | 5.0 |
Cell Differentiation | 3 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics/metabolism | 2 | 3.0 |
